Tau antisense oligomers and uses thereof
US11077132B2 · kind B2 · utility
0Cited by
35References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 4, 2016 |
| Grant date | Aug 3, 2021 |
| Priority date | — |
| Expiry date | Feb 4, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/346
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.